

# UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	· FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/897,476	07/03/2001	Edoardo Camenzind	017753-148	2491
7590 04/09/2004			EXAMINER	
Norman H. Stepno, Esquire			RAMANA, ANURADHA	
BURNS, DOANE, SWECKER & MATHIS, L.L.P. P.O. Box 1404			ART UNIT	PAPER NUMBER
Alexandria VA 22313-1404			3732	

DATE MAILED: 04/09/2004

Please find below and/or attached an Office communication concerning this application or proceeding.

	Application No.	Applicant(s)			
	09/897,476	CAMENZIND ET AL.			
Office Action Summary	Examiner	Art Unit			
	Anu Ramana	3732			
The MAILING DATE of this communication appears on the cover sheet with the correspondence address Period for Reply					
A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) FROM THE MAILING DATE OF THIS COMMUNICATION.  - Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.  - If the period for reply specified above is less than thirty (30) days, a reply within the statutory minimum of thirty (30) days will be considered timely.  - If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.  - Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133).  Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).					
Status					
1) Responsive to communication(s) filed on 12 March 2004.					
<b>,</b> — , — , —	$m{r}=$				
3) Since this application is in condition for allowance except for formal matters, prosecution as to the merits is					
closed in accordance with the practice under Ex parte Quayle, 1935 C.D. 11, 453 O.G. 213.					
Disposition of Claims					
<ul> <li>4)  Claim(s) 1-10,13-16 and 19 is/are pending in the application.</li> <li>4a) Of the above claim(s) is/are withdrawn from consideration.</li> <li>5)  Claim(s) is/are allowed.</li> <li>6)  Claim(s) 1-5,8,10,13-16 and 19 is/are rejected.</li> <li>7)  Claim(s) 6 and 7 is/are objected to.</li> </ul>					
8) Claim(s) are subject to restriction and/or election requirement.					
Application Papers					
9) The specification is objected to by the Examine		the boother Properties			
10)⊠ The drawing(s) filed on <u>17 October 2002</u> is/are: a)⊠ accepted or b)□ objected to by the Examiner.					
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).  Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).					
11) The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.					
Priority under 35 U.S.C. § 119					
<ul> <li>12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).</li> <li>a) All b) Some * c) None of:</li> <li>1. Certified copies of the priority documents have been received.</li> <li>2. Certified copies of the priority documents have been received in Application No</li> <li>3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).</li> <li>* See the attached detailed Office action for a list of the certified copies not received.</li> </ul>					
Attachment(s)  1) Notice of References Cited (PTO-892)  2) Notice of Draftsperson's Patent Drawing Review (PTO-948)  3) Information Disclosure Statement(s) (PTO-1449 or PTO/SB/08) Paper No(s)/Mail Date	4)  Interview Summary Paper No(s)/Mail D 5)  Notice of Informal F 6)  Other:	(PTO-413) ate Patent Application (PTO-152)			



Application/Control Number: 09/897,476

Art Unit: 3732

### **DETAILED ACTION**

The indicated allowability of claims 11, 12, and 16 in the Final Rejection mailed on September 12, 2003 is withdrawn. The examiner sincerely apologizes for any inconvenience caused to the Applicants due to this action.

## Specification

The specification is objected to because of its layout and content. The following guidelines illustrate the preferred layout for the specification of a utility application. These guidelines are suggested for the applicant's use.

## Arrangement of the Specification

As provided in 37 CFR 1.77(b), the specification of a utility application should include the following sections in order. Each of the lettered items should appear in upper case, without underlining or bold type, as a section heading. If no text follows the section heading, the phrase "Not Applicable" should follow the section heading:

- (a) TITLE OF THE INVENTION.
- (b) CROSS-REFERENCE TO RELATED APPLICATIONS.
- (c) STATEMENT REGARDING FEDERALLY SPONSORED RESEARCH OR DEVELOPMENT.
- (d) INCORPORATION-BY-REFERENCE OF MATERIAL SUBMITTED ON A COMPACT DISC (See 37 CFR 1.52(e)(5) and MPEP 608.05. Computer program listings (37 CFR 1.96(c)), "Sequence Listings" (37 CFR 1.821(c)), and tables having more than 50 pages of text are permitted to be submitted on compact discs.) or REFERENCE TO A "MICROFICHE APPENDIX" (See MPEP § 608.05(a).
  - "Microfiche Appendices" were accepted by the Office until March 1, 2001.)
- (e) BACKGROUND OF THE INVENTION.
  - (1) Field of the Invention.
  - (2) Description of Related Art including information disclosed under 37 CFR 1.97 and 1.98.
- (f) BRIEF SUMMARY OF THE INVENTION.
- (g) BRIEF DESCRIPTION OF THE SEVERAL VIEWS OF THE DRAWING(S).
- (h) DETAILED DESCRIPTION OF THE INVENTION.
- (i) CLAIM OR CLAIMS (commencing on a separate sheet).
- (i) ABSTRACT OF THE DISCLOSURE (commencing on a separate sheet).
- (k) SEQUENCE LISTING (See MPEP § 2424 and 37 CFR 1.821-1.825. A "Sequence Listing" is required on paper if the application discloses a nucleotide or amino

Application/Control Number: 09/897,476 Page 3

Art Unit: 3732

acid sequence as defined in 37 CFR 1.821(a) and if the required "Sequence Listing" is not submitted as an electronic document on compact disc).

A brief description of the content of the specification organized according to the above layout is provided below.

## Content of Specification

- (a) <u>Title of the Invention</u>: See 37 CFR 1.72(a) and MPEP § 606. The title of the invention should be placed at the top of the first page of the specification unless the title is provided in an application data sheet. The title of the invention should be brief but technically accurate and descriptive, preferably from two to seven words may not contain more than 500 characters.
- (b) <u>Cross-References to Related Applications</u>: See 37 CFR 1.78 and MPEP § 201.11.
- (c) <u>Statement Regarding Federally Sponsored Research and Development</u>: See MPEP § 310.
- (d) Incorporation-By-Reference Of Material Submitted On a Compact Disc: The specification is required to include an incorporation-by-reference of electronic documents that are to become part of the permanent United States Patent and Trademark Office records in the file of a patent application. See 37 CFR 1.52(e) and MPEP § 608.05. Computer program listings (37 CFR 1.96(c)), "Sequence Listings" (37 CFR 1.821(c)), and tables having more than 50 pages of text were permitted as electronic documents on compact discs beginning on September 8, 2000.

Or alternatively, <u>Reference to a "Microfiche Appendix</u>": See MPEP § 608.05(a). "Microfiche Appendices" were accepted by the Office until March 1, 2001.

- (e) <u>Background of the Invention</u>: See MPEP § 608.01(c). The specification should set forth the Background of the Invention in two parts:
  - (1) <u>Field of the Invention</u>: A statement of the field of art to which the invention pertains. This statement may include a paraphrasing of the applicable U.S. patent classification definitions of the subject matter of the claimed invention. This item may also be titled "Technical Field."
  - (2) Description of the Related Art including information disclosed under 37

    CFR 1.97 and 37 CFR 1.98: A description of the related art known to the applicant and including, if applicable, references to specific related art and

Page 4

Application/Control Number: 09/897,476

Art Unit: 3732

problems involved in the prior art which are solved by the applicant's invention. This item may also be titled "Background Art."

- (f) Brief Summary of the Invention: See MPEP § 608.01(d). A brief summary or general statement of the invention as set forth in 37 CFR 1.73. The summary is separate and distinct from the abstract and is directed toward the invention rather than the disclosure as a whole. The summary may point out the advantages of the invention or how it solves problems previously existent in the prior art (and preferably indicated in the Background of the Invention). In chemical cases it should point out in general terms the utility of the invention. If possible, the nature and gist of the invention or the inventive concept should be set forth. Objects of the invention should be treated briefly and only to the extent that they contribute to an understanding of the invention.
- (g) <u>Brief Description of the Several Views of the Drawing(s)</u>: See MPEP § 608.01(f). A reference to and brief description of the drawing(s) as set forth in 37 CFR 1.74.
- (h) Detailed Description of the Invention: See MPEP § 608.01(g). A description of the preferred embodiment(s) of the invention as required in 37 CFR 1.71. The description should be as short and specific as is necessary to describe the invention adequately and accurately. Where elements or groups of elements, compounds, and processes, which are conventional and generally widely known in the field of the invention described and their exact nature or type is not necessary for an understanding and use of the invention by a person skilled in the art, they should not be described in detail. However, where particularly complicated subject matter is involved or where the elements, compounds, or processes may not be commonly or widely known in the field, the specification should refer to another patent or readily available publication, which adequately describes the subject matter.
- (i) Claim or Claims: See 37 CFR 1.75 and MPEP § 608.01(m). The claim or claims must commence on separate sheet or electronic page (37 CFR 1.52(b)(3)). Where a claim sets forth a plurality of elements or steps, each element or step of the claim should be separated by a line indentation. There may be plural indentations to further segregate subcombinations or related steps. See 37 CFR 1.75 and MPEP § 608.01(i)-(p).
- (j) Abstract of the Disclosure: See MPEP § 608.01(f). A brief narrative of the disclosure as a whole in a single paragraph of 150 words or less commencing on a separate sheet following the claims. In an international application, which has entered the national stage (37 CFR 1.491(b)), the applicant need not submit an abstract commencing on a separate sheet if an abstract was published with the international application under PCT Article 21. The abstract that appears on the cover page of the pamphlet published by the International Bureau (IB) of the

Application/Control Number: 09/897,476

Art Unit: 3732

World Intellectual Property Organization (WIPO) is the abstract that will be used by the USPTO. See MPEP § 1893.03(e).

(k) <u>Sequence Listing.</u> See 37 CFR 1.821-1.825 and MPEP §§ 2421-2431. The requirement for a sequence listing applies to all sequences disclosed in a given application, whether the sequences are claimed or not. See MPEP § 2421.02.

Appropriate correction is required.

### Claim Objections

Claim 5 is objected to because of the following informalities. In line 3, for clarity it is suggested that the phrase "and spaced apart .....device," be replaced with ", said perforating elements being spaced apart along ... device." Appropriate correction is required.

## Claim Rejections - 35 USC § 102

The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action:

A person shall be entitled to a patent unless -

(e) the invention was described in (1) an application for patent, published under section 122(b), by another filed in the United States before the invention by the applicant for patent or (2) a patent granted on an application for patent by another filed in the United States before the invention by the applicant for patent, except that an international application filed under the treaty defined in section 351(a) shall have the effects for purposes of this subsection of an application filed in the United States only if the international application designated the United States and was published under Article 21(2) of such treaty in the English language.

Claims 1-5, 8, 10 and 13-16 are rejected under 35 U.S.C. 102(e) as being anticipated by Naimark et al. (US 6,638,246).

Regarding claims 1-5, 8, 10 and 13-16, Naimark et al. disclose a device 60 for administering a biologically active material or "composition" in a wall of a blood vessel having a plurality of solid micro-needles (or "perforating parts") 64 with a diameter of about 100 microns or 0.1mm ("means for entering") disposed on an outer surface 67a of an inflatable or "radially expandable" balloon 60 and a biologically active material on the outer surface 67a ("dispensing means") of balloon 60 wherein the micro-needles 64 contact the surface or wall of the blood vessel to create micro- or nano-pores and the biologically active material seeps into the micro- or nano-pores (col. 1, lines 8-18, col. 2, lines 14-26, col. 4, lines 34-47, col. 5, lines 60-67 and col. 7, lines 1-27, Figures 6A-6C).

Application/Control Number: 09/897,476

Art Unit: 3732

Regarding claim 10, Naimark et al. disclose that an embodiment of device 60 can have an internal compartment and the wall of balloon 60 can be porous to allow delivery of the biologically active composition (col. 7, lines 29-33).

## Claim Rejections - 35 USC § 103

The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:

(a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negatived by the manner in which the invention was made.

Claim 1-5, 8-10, 13-16 and 19 are rejected under 35 U.S.C. 103(a) as being unpatentable over Wyzgala et al. (US 6,096,054) and Lin et al. (US 5,792,105).

Wyzgala et al. disclose a device 28 for administering a composition in a wall of a blood vessel or duct of a human body including: a balloon or radially expandable entry means 34 with perforating parts or elements in the form of an abrasive 36 disposed on the outer surface of entry means 34 for entering an inner surface of a duct wall to make openings in the form of a pinprick (Figure 1B, col. 1, lines 11-13, col. 2, lines 19-21, col. 4, lines 51-67 and col. 5, lines 1-14).

Although Wyzgala et al. do not disclose that abrasive 36 can make openings in the form of a pinprick in a size range of 0.05 mm to 1.0 mm, it would have been an obvious matter of design choice to select a size of abrasive to make pinpricks in a size range of 0.05 mm to 1.0 mm, since such a modification would have involved a mere change in the size of a component (namely abrasive particle size). A change in size is generally recognized as being within the level of ordinary skill in the art. In re Rose, 105 USPQ 237 (CCPA 1955).

Wyzgala et al. do not disclose a dispensing means.

Lin et al. disclose a multi-lumen medication dispensing means or balloon catheter 10.

It would have been a matter of obvious design choice to a person of ordinary skill in the art at the time the invention was made to have oriented the Lin et al. device around the Wyzgala et al. device because the dispenser means surrounding the entry means is merely a method of

Art Unit: 3732

orienting the separately claimed elements, i.e, dispenser means and entry means which have not structurally been tied together and is therefore not given patentable weight.

Regarding claim 9, Lin et al. further disclose that balloon 10 has an inner balloon wall 12, an outer balloon wall 14 and dividers 17 which define channels or conduits 16 therebetween. Each channel 16 terminates in an outlet 20 on the outer balloon wall 14 through which medication 19 is delivered (Figure 1 and col. 3, lines 21-31).

Regarding claim 10, Wyzgala et al. further disclose dispenser means 30 to have one or more holes 32 that allow fluid to flow in or out of the dispenser means.

Regarding claim 19, it would have been a matter of obvious design choice to a person of ordinary skill in the art at the time the invention was made to axially slide the Lin et al. device over the Wyzgala et al. device because the dispenser means being arranged to slide in relation to the entry means is merely a method of orienting the separately claimed elements, i.e, dispenser means and entry means which have not structurally been tied together and is therefore not given patentable weight.

## Allowable Subject Matter

Claims 6-7 are objected to as being dependent upon a rejected base claim, but would be allowable if rewritten in independent form including all of the limitations of the base claim and any intervening claims.

#### Conclusion

The prior art made of record and not relied upon is considered pertinent to applicant's disclosure.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Anu Ramana whose telephone number is (703) 306-4035. The examiner can normally be reached Monday through Friday between 8:00 am to 5:00 pm.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Kevin Shaver can be reached at (703) 308-2582. The fax phone number for the organization where this application or proceeding is assigned is 703-872-9306.

Application/Control Number: 09/897,476 Page 8

Art Unit: 3732

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

ARAnuado famara April 7, 2004

> John J. Wilson Primary Examiner